Novo Nordisk A/S
Company Snapshot
Founded: 1923
Entity Type: Public
Employees: 77,349
Region: North America
Revenue: $42,122.4 Millions
Revenue Year: 2024
Headquarter: Bagsvaerd, Denmark
Key Geographics: North America, EMEA (Europe, Middle-east and Africa), China, Rest of the World
Corporate Address: Novo Allé, 2880 Bagsvaerd Denmark Tel. +45-4444-8888 www.novonordisk.com
Company Overview
Novo Nordisk operates in two business segments: Diabetes and obesity care and rare diseases. Diabetes and obesity care includes therapeutics for diabetes, cardiovascular, obesity, and emerging therapy areas. The rare disease includes products for rare blood disorders, endocrine disorders, and hormone replacement therapies. The company has a strong pipeline in technology platforms, including proteins and peptides, stem cells, oligonucleotides, and gene therapy. The company has a presence in nearly 80 countries
Financial Highlights (FY 2024)
Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***
This information is available for BCC Research members only.
Company's Business Segments
- Diabetes and Obesity Care : Diabetes, Obesity, Cardiovascular, Emerging therapy areas
- Rare Disease : Rare blood disorders, Rare endocrine disorders, Hormone replacement therapy
Applications/End User Industries
- Government Agencies
- Retail Customers
- Private Payers
- Pharmacy Business Management (PBM)
- Healtcare Organisations
- Health Insurance Companies
BCC Research Beacon 